Extending
horizons

Scroll

The first global
all organ company

Founded in 1998, XVIVO is the only medical technology company
dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.

Business Areas

XVIVO is the forerunner in life-extending technologies for organs. We lead the way by following the science.

XVIVO Thorax

Clinically optimized solutions for organ, tissue and cell preservation and perfusion in connection with transplantation.

Find out more

XVIVO Abdominal

Devices for oxygenated machine perfusion during preconditioning, preservation, reconditioning and transport of organs.

Find out more

Annual Report

The Annual Report is available in pdf format and in ESEF format (European Single Electronic Format) and is also available at www.xvivoperfusion.com.

A printed version of the Annual Report 2020 can be ordered by phone +46 (0) 31 788 21 50 or by email info@xvivogroup.com.

Downloads
  • XVIVO’s Annual Report 2020 PDF
  • XVIVO’s Annual Report 2020 ESEF

XVIVO Share

The XVIVO share is listed on Nasdaq Stockholm mid cap list and has the ticker symbol XVIVO.

The share has been listed on Nasdaq Stockholm mid cap since November 28, 2016. The XVIVO Perfusion share was before that listed on Nasdaq First North since October 8, 2012.

NASDAQ STOCKHOLM

XVIVO Perfusion

00-00-00 00:00:00 CET

SHARE PRICE IN SEK

0,00

CHANGE

0%